Hangzhou Biotest Biotech Co Ltd (688767) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hangzhou Biotest Biotech Co Ltd (688767) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥28.39 Million ≈ $4.15 Million USD) by net assets (CN¥2.34 Billion ≈ $342.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688767 market cap for the company's overall valuation and market capitalisation.
Hangzhou Biotest Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hangzhou Biotest Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Hangzhou Biotest Biotech Co Ltd for real-time trading data and today's change.
Hangzhou Biotest Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hangzhou Biotest Biotech Co Ltd ranked by their cash flow conversion efficiency. Review 688767 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JOST Werke AG
XETRA:JST
|
0.081x |
|
First Financial Corporation Indiana
NASDAQ:THFF
|
0.027x |
|
Beijing SL Pharmaceutical Co Ltd
SHE:002038
|
0.013x |
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
0.047x |
|
SG Fleet Group Ltd
AU:SGF
|
-0.064x |
|
Zhejiang Hongchang Electrical Technology Co. Ltd.
SHE:301008
|
0.052x |
|
Msscorps Co Ltd
TW:6830
|
0.071x |
|
Infund Holding Co Ltd
SHE:002141
|
0.075x |
Annual Cash Flow Conversion Efficiency for Hangzhou Biotest Biotech Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hangzhou Biotest Biotech Co Ltd from 2017 to 2025. Also see Hangzhou Biotest Biotech Co Ltd (688767) total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.37 Billion ≈ $346.99 Million |
CN¥106.47 Million ≈ $15.58 Million |
0.045x | -15.92% |
| 2024-12-31 | CN¥2.41 Billion ≈ $353.00 Million |
CN¥128.83 Million ≈ $18.85 Million |
0.053x | -1.60% |
| 2023-12-31 | CN¥2.42 Billion ≈ $354.23 Million |
CN¥131.38 Million ≈ $19.23 Million |
0.054x | -80.22% |
| 2022-12-31 | CN¥2.56 Billion ≈ $374.94 Million |
CN¥703.21 Million ≈ $102.90 Million |
0.274x | -36.29% |
| 2021-12-31 | CN¥2.11 Billion ≈ $308.49 Million |
CN¥908.12 Million ≈ $132.89 Million |
0.431x | -57.22% |
| 2020-12-31 | CN¥443.02 Million ≈ $64.83 Million |
CN¥446.07 Million ≈ $65.27 Million |
1.007x | +394.07% |
| 2019-12-31 | CN¥125.95 Million ≈ $18.43 Million |
CN¥25.67 Million ≈ $3.76 Million |
0.204x | -5.51% |
| 2018-12-31 | CN¥98.15 Million ≈ $14.36 Million |
CN¥21.17 Million ≈ $3.10 Million |
0.216x | +142.81% |
| 2017-12-31 | CN¥79.63 Million ≈ $11.65 Million |
CN¥7.07 Million ≈ $1.04 Million |
0.089x | -- |
About Hangzhou Biotest Biotech Co Ltd
Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, veterinary test, drug of abuse, infectious diseases, and other diagnostic rapid test. It also provides m… Read more